4D Molecular Therapeutics develops customized gene therapies using a proprietary vector platform optimized through directed evolution, targeting diseases in ophthalmology, pulmonology, and cardiology. Their products aim to provide curative treatments for conditions with significant unmet medical needs, such as reducing the treatment burden for wet age-related macular degeneration.

Aera Therapeutics utilizes a protein nanoparticle (PNP) delivery platform that self-assembles from endogenous human proteins to package and transfer nucleic acid cargo. This technology addresses the limitations of current delivery methods for genetic medicines, enabling broader therapeutic applications.

Aktis Oncology develops precision radiopharmaceuticals that utilize targeted alpha-emitting particles to treat solid tumors in cancers with limited treatment options. Their technology aims to enhance the efficacy of cancer therapies by delivering localized radiation directly to cancer cells, minimizing damage to surrounding healthy tissue.

The startup develops an investigational enzyme replacement therapy that combines recombinant human alpha-N-acetylglucosaminidase with a peptide derived from insulin-like growth factor 2. This therapy targets rare pediatric neurodegenerative diseases, providing a potential treatment option for children suffering from these debilitating conditions.

Alys Pharmaceuticals conducts research and development focused on immuno‑dermatology, creating targeted therapies for dermatologic immune disorders. Its pipeline includes multi‑platform programs such as ALY‑301, a mast cell‑selective c‑Kit inhibitor currently in Phase 1/1b trials for chronic urticaria, aiming to address unmet patient needs. The company monetizes its products through commercial drug sales and licensing agreements upon regulatory approval.

Balance is a digital payments platform that streamlines B2B transactions by offering features such as instant credit decisioning, flexible payment terms, and automated accounts receivable management. This solution reduces processing costs and enhances the purchasing experience for both buyers and vendors across the supply chain.

BARO operates a fashion rental marketplace enabling women to access luxury apparel at a reduced cost. Users can also generate income by lending their own high-end clothing items to others on the platform. This service promotes affordability and sustainability within the luxury fashion consumption model.

BioAtla develops Conditionally Active Biologics (CABs) that are engineered to activate selectively in the tumor microenvironment, enhancing tumor selectivity and reducing on-target toxicity. This technology aims to improve the therapeutic index of cancer treatments, providing safer and more effective immunotherapies.

BIOS Health develops neural interfaces and AI technology to read and write neural data, enabling real-time analysis of the nervous system's signals. This approach addresses the malfunctioning signals that can lead to diseases, facilitating the creation of targeted pharmaceuticals and software-delivered therapies.

Capra Biosciences develops bioreactor technology that converts industrial byproducts and waste into bio-based materials, addressing the challenge of resource inefficiency in waste management. This process not only reduces environmental impact but also creates valuable materials for various applications, enhancing sustainability in manufacturing.

Cardeas Pharma focuses on the early-phase development of inhaled antibiotics specifically designed to target respiratory infections. Their approach aims to improve treatment efficacy and patient compliance by delivering medication directly to the site of infection in the lungs.

Cen utilizes blockchain technology to create a crowdsourced knowledge base that combines human and artificial intelligence, enabling real-time learning and context-aware interactions. The platform addresses the centralization of AI data ownership and the fragility of AI decision-making by allowing users to maintain control over their data while contributing to a collective intelligence resource.

COGNETIX offers Persona AI, a real-time customer behavior modeling platform that utilizes machine learning to analyze large datasets and create dynamic consumer personas. This technology addresses the challenge of data distortion and signal gaps, enabling businesses to optimize marketing campaigns and improve customer engagement through actionable insights.

CuraSen Therapeutics develops orphan drugs targeting neurodegenerative diseases by utilizing advanced pharmacological approaches to enhance neuroprotection and promote neuronal health. The company focuses on addressing the unmet medical needs of patients suffering from conditions like Alzheimer's and Parkinson's, where current treatment options are limited.

Enthera develops first-in-class biologics targeting the IGFBP3/TMEM219 pathway to preserve and restore organ cell function in patients with severe autoimmune disorders. The company focuses on creating disease-modifying treatments for conditions such as Type 1 Diabetes and Inflammatory Bowel Disease, addressing the lack of effective therapies in this area.

Eve is a customizable AI assistant designed specifically for the legal profession, enabling attorneys to efficiently draft legal documents, analyze case data, and manage discovery processes. By automating time-consuming tasks, Eve allows law firms to handle more cases and improve their operational efficiency without increasing headcount.

FORME is a digital fitness platform that combines smart home gym equipment with live and on-demand personal training sessions, offering tailored strength training and recovery programs. This solution addresses the challenge of accessing personalized fitness guidance and high-quality resistance training in a home environment, catering to users of all experience levels.

HARM provides an AI-powered platform for individuals experiencing harm to quickly access immediate, trusted support. The system intelligently identifies the nature of the reported harm and routes users directly to appropriate, city-approved advocacy, legal, or housing resources. This streamlined process eliminates confusion while generating de-identified data insights to help municipal leaders optimize community support services.

<name>Hi</name> <description>Hi provides a licensed crypto‑fiat neobank platform that enables users to trade over 100 cryptocurrencies alongside traditional fiat currencies. The app combines trading, yield‑earning savings accounts, and payment functionality in a single mobile interface. Users can set flexible crypto savings goals and withdraw funds at any

OppDoor provides technology-enabled services that enhance online selling efficiency on marketplaces like Amazon, Walmart, and Etsy through the integration of AI and data analytics. The company addresses the challenges of inventory management and sales optimization, enabling sellers to increase their revenue and streamline operations.

Om provides access to massive, internally generated datasets detailing proteome-wide small molecule binding data. Researchers can programmatically query billions of protein and small molecule interaction data points to identify therapeutic opportunities instantly. The platform leverages synthetic biology and pico-scale engineering to accelerate the transition from hypothesis to launching a discovery program.

The startup operates a web portal that facilitates direct, commission-free connections between artists, companies, producers, and programmers through a searchable directory featuring presentation sheets, contact information, and multimedia content. This platform addresses the challenge of fragmented communication in the creative industry by enabling streamlined access to programming talent and resources.

The startup offers an AI-driven platform that connects businesses with suitable partners throughout their innovation journey. By leveraging machine learning algorithms, it enhances strategic collaboration, enabling companies to identify and engage with startups that align with their specific needs.

Veralox Therapeutics is developing small molecule therapeutics that inhibit the 12-Lipoxygenase pathway to treat Heparin-Induced Thrombocytopenia (HIT) and Type 1 Diabetes (T1D). By targeting this enzyme, the company aims to reduce proinflammatory metabolites that contribute to platelet activation in HIT and enhance insulin production in T1D.